Ferroquine (SSR97193)

DRUG3 trials

Sponsors

Sanofi

Conditions

MalariaPlasmodium Falciparum Infection

Phase 1

A Comparative Safety and Activity Study With Ferroquine Associated With Artesunate Versus Amodiaquine Associated With Artesunate in African Adult Patients With Uncomplicated Malaria

CompletedNCT00563914

Start: 2007-10-31End: 2008-11-30Updated: 2009-12-21

Phase 2

Dose Ranging Study of Ferroquine With Artesunate in African Adults and Children With Uncomplicated Plasmodium Falciparum Malaria

TerminatedNCT00988507

SanofiPlasmodium Falciparum Infection

Start: 2009-10-31End: 2010-11-30Target: 440Updated: 2011-06-28

Study to Investigate the Clinical and Parasiticidal Activity and Pharmacokinetics of Different Doses of Artefenomel and Ferroquine in Patients With Uncomplicated Plasmodium Falciparum Malaria

CompletedNCT03660839

SanofiPlasmodium Falciparum Infection

Start: 2018-09-11End: 2019-11-06Updated: 2022-03-21

Related Papers

Randomized, open-label, phase 2a study to evaluate the contribution of artefenomel to the clinical and parasiticidal activity of artefenomel plus ferroquine in African patients with uncomplicated Plasmodium falciparum malaria

Malaria Journal2023-01-0315 citations

Effectiveness of antimalarial drug combinations in treating concomitant urogenital schistosomiasis in malaria patients in Lambaréné, Gabon: A non-randomised event-monitoring study

PLoS neglected tropical diseases2022-10-319 citations

Phase 2a, Open-Label, 4-Escalating-Dose, Randomized Multicenter Study Evaluating the Safety and Activity of Ferroquine (SSR97193) Plus Artesunate, versus Amodiaquine Plus Artesunate, in African Adult Men with Uncomplicated Plasmodium falciparum Malaria

American Journal of Tropical Medicine and Hygiene2017-08-0229 citations

Ferroquine and artesunate in African adults and children with Plasmodium falciparum malaria: a phase 2, multicentre, randomised, double-blind, dose-ranging, non-inferiority study.

2015-09-0351 citations